These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16467735)

  • 1. Phosphate binders.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):15-6. PubMed ID: 16467735
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Savica V; Calò LA; Monardo P; Santoro D; Bellinghieri G
    Nephrol Dial Transplant; 2006 Aug; 21(8):2065-8. PubMed ID: 16766546
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate binder usage in kidney failure patients.
    Bleyer AJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):941-7. PubMed ID: 12783590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate binders in CKD: chalking out the differences.
    Rees L; Shroff RC
    Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral phosphate binders in patients with kidney failure.
    Tonelli M; Pannu N; Manns B
    N Engl J Med; 2010 Apr; 362(14):1312-24. PubMed ID: 20375408
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphorus management in end-stage renal disease.
    Finn WF
    Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of phosphate binders: data from contributors to the European Practice Database.
    Elseviers M; De Vos JY
    J Ren Care; 2009 Mar; 35 Suppl 1():14-8. PubMed ID: 19222726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phosphate binder up to date].
    Shigematsu T; Sakaguchi T; Orita H
    Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.
    Jamal SA; Fitchett D; Lok CE; Mendelssohn DC; Tsuyuki RT
    Nephrol Dial Transplant; 2009 Oct; 24(10):3168-74. PubMed ID: 19622572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
    Skaguchi T; Shigematsu T
    Clin Calcium; 2009 Jun; 19(6):844-51. PubMed ID: 19483280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
    Evenepoel P; Meijers B
    Nat Rev Nephrol; 2012 Nov; 8(11):615-6. PubMed ID: 23045230
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.
    Gray NA; Krishnasamy R; Vardesh DL; Hollett PR; Anstey CM
    Nephrology (Carlton); 2011 Nov; 16(8):688-96. PubMed ID: 21649793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
    Fournier A; Oprisiu R; Albu AT; Dungaciu M; El Esper N; Mornière P
    Am J Kidney Dis; 2000 Jun; 35(6):1248-50. PubMed ID: 10877727
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphate binders in CKD: bad news or good news?
    Drüeke TB; Massy ZA
    J Am Soc Nephrol; 2012 Aug; 23(8):1277-80. PubMed ID: 22797178
    [No Abstract]   [Full Text] [Related]  

  • 16. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
    Curran MP; Robinson DM
    Drugs; 2009 Nov; 69(16):2329-49. PubMed ID: 19852531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.
    Galassi A; Spiegel DM; Bellasi A; Block GA; Raggi P
    Nephrol Dial Transplant; 2006 Nov; 21(11):3215-22. PubMed ID: 16877490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.
    Suki WN; Zabaneh R; Cangiano JL; Reed J; Fischer D; Garrett L; Ling BN; Chasan-Taber S; Dillon MA; Blair AT; Burke SK
    Kidney Int; 2007 Nov; 72(9):1130-7. PubMed ID: 17728707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic analysis of phosphate binders cost-effectiveness in the RISCAVID study.
    Panichi V; Rosati A; Di Giorgio A; Scatena A; Bigazzi R; Grazi G; Migliori M; Paoletti S; Manca Rizza G; Casani A; Sgambato A; Ruggeri M
    Blood Purif; 2015; 39(1-3):174-180. PubMed ID: 25765293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology, efficacy and safety of oral phosphate binders.
    Hutchison AJ; Smith CP; Brenchley PE
    Nat Rev Nephrol; 2011 Sep; 7(10):578-89. PubMed ID: 21894188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.